Jpmorgan Chase & CO Pharvaris N.V. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Pharvaris N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 253 shares of PHVS stock, worth $5,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares

253

Holding current value

$5,148

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$15.73 - $21.4 $3,979 - $5,414	253 New	253 $4,000
Q1 2024 May 10, 2024	BUY	$21.26 - $32.07 $62,929 - $94,927	2,960 Added 1557.89%	3,150 $72,000
Q4 2023 Feb 12, 2024	BUY	$15.2 - $28.05 $2,888 - $5,329	190 New	190 $5,000
Q2 2023 Aug 11, 2023	BUY	$7.82 - $16.0 $1,180 - $2,416	151 New	151 $2,000
Q2 2022 Aug 11, 2022	SELL	$16.35 - $27.5 $56,064 - $94,297	-3,429 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$15.98 - $19.65 $216,289 - $265,962	-13,535 Reduced 79.79%	3,429 $64,000
Q4 2021 Feb 10, 2022	BUY	$13.28 - $18.0 $14,076 - $19,080	1,060 Added 6.66%	16,964 $268,000
Q3 2021 Nov 12, 2021	BUY	$13.14 - $20.97 $208,978 - $333,506	15,904 New	15,904 $274,000

Others Institutions Holding PHVS

# of Institutions

Shares Held

39.6M

Call Options Held

Put Options Held

General Atlantic LLC New York, NY

7.53M
Shares

$153 Million
3.99% of portfolio
Foresite Capital Management Iv, LLC Larkspur, CA

4.4M
Shares

$89.5 Million
53.23% of portfolio
Ven Bio Partners LLC San Francisco, CA

4.29M
Shares

$87.3 Million
65.3% of portfolio
Viking Global Investors LP

3.65M
Shares

$74.3 Million
0.26% of portfolio
Vr Adviser, LLC New York, NY

3.4M
Shares

$69.1 Million
6.51% of portfolio

View Full List

About Pharvaris N.V.

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $687M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

More about PHVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account